BioLineRx Ltd BLRX Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125

12:40 EDT 2 Oct 2019 | BioPortfolio Report Blog

BioLineRx Ltd BLRX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


BioLineRx Ltd BioLineRx is a clinical stage biopharmaceutical company that focuses on development of products related to cancer and immunology. Its pipeline product BL8040 is a short peptide which is in Phase IIb clinical trial studies for acute myeloid leukemia AML, Phase III studies for autologous transplantation and completed Phase IIa clinical trials for relapsed or refractory AML. The company's other pipeline drug candidate AGI134 is a synthetic alphagal immunotherapy finds application in the treatment of solid tumors. BioLineRx's only product BL5010 is a novel medical device indicated for nonsurgical removal of skin lesions. BioLineRx is headquartered in Modi'in, Israel.

BioLineRx Ltd Key Recent Developments

Aug 06,2019: BioLineRx reports second quarter 2019 financial results and provides corporate update

May 14,2019: BioLineRx reports first quarter 2019 financial results and provides corporate update

Nov 08,2018: BioLineRx reports significant progress across oncology programs and provides third quarter financial update

Aug 13,2018: BioLineRx reports second quarter 2018 financial results

Jun 13,2018: BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: BioLineRx Ltd BLRX Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125


More From BioPortfolio on "BioLineRx Ltd BLRX Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...